Q-omics provides the consensus-scored KLF1 profile across patient tissues and cancer cell-line models. KLF1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, KLF1 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, KLF1 RNA expression shows 11,178 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight CESC, COAD, and THYM as cancer lineages where KLF1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KLF1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KLF1 survival associations across molecular data types. KLF1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KLF1 RNA expression–survival associations across cancer types. High KLF1 expression shows unfavorable associations in ACC and UCEC, but favorable associations in CESC, HNSC, LGG and STAD. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify CESC as the clearest survival context for KLF1 RNA expression.
This table summarizes KLF1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 2. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for KLF1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KLF1 shows higher tumor expression in COAD, HNSC, BRCA, KIRC, UCEC and STAD. The COAD box plot shows higher KLF1 RNA expression in tumor versus normal tissue (log2 FC = +0.270, t-test p < 0.001).
This table shows molecular features associated with KLF1 in patient tissues and cancer cell lines. In patient samples, KLF1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, KLF1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
